The 310,458 shares sold on the "buy on close" order went in at 16:00:01 but in further afterhours action an additional 348,000 shares were sold at 1-2 cents above the close. Let's hope that it's a hint of Monday's action
1. If the science is effective, which most us know it is, there are contracts from the launch that are supposedly generating money.
2. Murphy keeps treating everything as if it's a state secret (very much like mom and pop business owners) and until he starts to act like the CEO of a public company, the shorts will continue to ream him out.
3. Hopefully, the earnings will be decent.
4. Unless Murphy discloses the number of contracts in the call, he will continue to be the best friend of the shorts and we, as longs, will pay the price.
5. WHERE IS THE GUIDANCE???
It's all up to what Murphy says. If he actually reveals the number of active contracts and they a out to a decent number, 7 to 8 is achievable. If he continues to be secretive and tells the street nothing, we will stay in the same range as the current PPS.
So far, Murphy has been the shorts best friend so hopefully, his actions in August may mirror what a CEO should do.
Years ago, Jesse Livermore stated that "If you choose to be a public company, your most important product is your share price."
Murphy forgot to read that chapter at 'B' school.
The Problem is that of the two "announced buybacks, totaling 92 million, they have only bought 10 million worth of stock. This has decimated their credibility so Matt basically releases nothing regarding company progress and the longs bail out at every opportunity trying to break even. I'm far too long this stock and the August earnings will be the drop dead event. If they can't eke out a profit on near 100 million in business, the stock will die a painful death. Also, it's been 7 months since the announcement of the TF deal and absolutely nothing has happened except for the "we're making progress" BS from IR
The smartest thing to do is put bigdope on ignore like the rest of us have already done. He's just a poor little obsessed simpleton craving attention. Not worth the time to read or reply
This idiot is used to collapse. He's been pumping Gigoptix for years which is an historic loser so he's very accustomed to losing money
Matthew, You're right considering that the liver model is proven and starting to sell but, with Murphy unwilling to give the analysts any information about the level of sales or contracts, none of them will stick their necks out to recommend the stock. The secondary was ill timed and could easily have been done after earnings in August and, if the earnings show progress, the secondary would not have generated a beating on the share price. The ONVO problem is simply with management! Murphy is obviously a good scientist but, if he can't see that todays markets are news driven in every sense of the way, he's playing right into the hands of the short sellers who have been eating his lunch. In order to attract institutional buyers he was forced to haircut the rest of us who are long. The best thing that can be hoped for is a buyout by a decent sized pharma that has the management ability to instill some confidence about the real business prospects of the thesis. The concept is fantastic but the management is lacking.
You hit it on the head. Agreed that Murphy can not give out specific numbers within in the quiet period but nothing prohibits him from general information on the number of contracts or customers during a presentation. Once again, Keith drops the ball and fails to impress institutional investors. No info....No Money
If Keith gets up in front of institutional investors and tries to keep them in the dark about existing contracts, they'll walk out and Onvo won't move a nickel. He better start acting like the CEO of a PUBLIC
company if he wants to play with the big kids
You have no idea whatsoever of the HFT tactics and what happens in the real market. go back to bashing for .25 per post. Someday you might have enough to actually buy a share of something
Keith is a scientist who has no concern for burning the shorts or taking care of current shareholders. If he were more of a CEO, he would have announced the number of contracts before the secondary which would have taken care of the shorts. It remains to be seen whet here or not he'll step up to the plate with some decent guidance.
The problem is not the likes of Traskie, it is the fact that Murphy will not adhere to the rules of the street. Guidance is the name of the game and he treats whatever contracts they have like they are national secrets. When money managers can't get a straight answer from the company management, they simply move away from the stock which emboldens the shorts to get more aggressive. Nobody is arguing with the science and that it is viable in todays drug development world. The problem is simply that a scientist is basically competing with Wall Street short sellers and Murphy is either ill equipped to do the job or doesn't care about shareholders. Just FYI, I'm extremely long the stock and extremely #$%$ with Murphy's business sense.